Quantcast
Home > Quotes > NKTR
NKTR

Nektar Therapeutics Common Stock (NKTR) Quote & Summary Data

$38.19
*  
0.54
1.43%
Get NKTR Alerts
*Delayed - data as of Nov. 15, 2018  -  Find a broker to begin trading NKTR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    NKTR After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 38.19 / $ 38.49
1 Year Target
79.5
Today's High / Low
$ 38.26 / $ 35.97
Share Volume
3,492,668
50 Day Avg. Daily Volume
2,486,294
Previous Close
$ 37.65
52 Week High / Low
$ 111.36 / $ 33.50
Market Cap
6,610,124,972
P/E Ratio
9.64
Forward P/E (1y)
10.29
Earnings Per Share (EPS)
$ 3.96
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.3

Intraday Chart

Shares Traded

Share Volume:
3,492,668
50 Day Avg. Daily Volume:
2,486,294

P/E Ratio

P/E Ratio:
9.64
Forward P/E (1y):
10.29
Earnings Per Share (EPS):
$ 3.96

Trading Range

The current last sale of $38.19 is 14.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 38.26 $ 111.36
 Low: $ 35.97 $ 33.50

Company Description (as filed with the SEC)

Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We refer to our drug candidates where we retain at least U.S. commercial rights as "proprietary programs" and our other drug candidate programs that we have licensed U.S. and potentially other commercial rights to collaboration partners as "collaboration partner programs.  ... More ...  


Risk Grade

Where does NKTR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 37.41
Open Date:
Nov. 15, 2018
Close Price:
$ 38.19
Close Date:
Nov. 15, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x